Deep Track Capital

Activity in this selectionwing-vc-f500ee32

By stage

Series B2

Series C+2

Biotech4

United States3

United Kingdom1

4 in this selection

Jul 14

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries B

Role not disclosed

Jun 17

Develops novel antibody treatments for immunological and inflammatory disorders

$65MSeries C

Role not disclosed

Apr 15

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Mar 31

Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders

$100MSeries B

Role not disclosed